Pediatric Drug Development: Optimizing Extrapolation Blog Pediatric Drug Development: Optimizing Extrapolation Drug development in pediatrics continues to be a substrate for the application of innovative tools…Certara2021年9月1日
Gene Therapy Based Precision Medicine Therapeutics: Clinical Pharmacology & Translational Science Considerations Blog Gene Therapy Based Precision Medicine Therapeutics: Clinical Pharmacology & Translational Science Considerations The era of gene therapy may have started a couple of decades ago, but approvals…Certara2021年8月13日
Succeeding in Value Communication: Introduction Blog バリューコミュニケーションの成功:新薬の紹介 Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding…Certara2021年8月5日
Why You Should Participate in the Voluntary FDA Oncology Center of Excellence Assessment Aid Program Blog Why You Should Participate in the Voluntary FDA Oncology Center of Excellence Assessment Aid Program In 2018, the FDA’s Oncology Center of Excellence developed an Assessment Aid document to help…Certara2021年7月21日
Key Considerations to Ensure Maximal Probability of Antibody Drug Conjugate Development Success Blog 抗体薬物複合体開発の成功の確率を最大化するための主な検討事項 Antibody drug conjugates (ADC) are a unique way to obliterate tumor cells and represent an…Certara2021年7月8日
Maximizing Oligonucleotide Therapeutic Development: Pre-clinical and Translational Considerations Blog Maximizing Oligonucleotide Therapeutic Development: Pre-clinical and Translational Considerations This is the second of three blog posts discussing best practices for developing oligonucleotide therapeutics.…Certara2021年6月25日
Top 10 Benefits to Integrating the Simcyp PBPK Simulator into your Drug Development Program Blog Simcyp PBPK Simulatorをお客様の医薬品開発プログラムに統合する10のメリット Per US FDA’s recent paper on the topic, Physiologically based Pharmacokinetic (PBPK) modeling & simulation…Certara2021年6月22日
Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers Blog Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…Certara2021年6月18日
Watershed Moment for the Future of Cell Therapy Development – FDA Advisory Committee Meeting Blog Watershed Moment for the Future of Cell Therapy Development – FDA Advisory Committee Meeting Every FDA Advisory Committee meeting is unique, and the Cellular, Tissue, and Gene Therapies Advisory…Certara2021年6月15日
Why Your Regulatory Writers Need eCTD Authoring Templates Blog Why Your Regulatory Writers Need eCTD Authoring Templates If you’ve heard about eCTD authoring template suites before, but you’re not sure what they…Certara2021年5月14日